Arvinas Holding Company (ARVN)
NASDAQ:ARVN
ARVN Stock Chart & Stats
$11.37
$0.30(1.54%)
At close: 4:00 PM EST
$11.37
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$5.90 - $14.51
Previous CloseN/A
Volume216.17K
Average Volume (3M)939.45K
Market Cap
$727.24M
Enterprise Value$595.83M
Total Cash (Recent Filing)$685.40M
Total Debt (Recent Filing)$8.50M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Apr 30, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,961,000
10 Day Avg. Volume869,346
30 Day Avg. Volume939,453
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.27
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda-6.12
Forecast
1Y Price Target
$16.45Price Target Upside44.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.37
Revenue Forecast (FY)$93.17M
Bulls Say, Bears Say
Bulls Say
Differentiation Versus Incumbent TherapiesThe degrader approach showed stronger reductions in LRRK2-related measures and urine biomarkers compared with a leading LRRK2 inhibitor, suggesting potential superiority in suppressing harmful signaling.
Pipeline Breadth And Development PlansCompany advancement of ARV-102 into progressive supranuclear palsy studies, alongside active programs in KRAS-driven cancers and lymphoma, coupled with sufficient runway, creates multiple clinical readouts that could drive valuation upside.
Target Engagement And BiomarkersARV-102 produced dose-dependent degradation of LRRK2 in cerebrospinal fluid and reduced neuroinflammatory and lysosomal biomarkers in Parkinson's patients, supporting brain target engagement and pathway modulation.
Bears Say
Market Size And Competitive PressureLimiting treatment to patients with a specific genetic form or the success of a competitor testing a broader patient population could significantly restrict the addressable market and commercial potential.
Safety And Long-term Pulmonary RiskTherapy-class links to lung effects mean longer-duration dosing and pulmonary monitoring are required to confirm chronic safety and rule out late-emerging toxicity.
Uncertain Clinical TranslationPharmacodynamic and biomarker improvements do not guarantee patient benefit, leaving uncertainty about whether observed target degradation will translate into meaningful clinical outcomes.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $5.90 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $727.24M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Apr 30, 2026 which is in 22 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Feb 24, 2026. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$0.513 by -$0.587.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.92.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 63,961,000 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$1.1 in its last earnings report, missing expectations of -$0.513. Following the earnings report the stock price went up 0.569%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.45 (44.68% Upside)
$16.45 (44.68% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 83.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $566.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.03%
12-Months-Change
Fundamentals
Return on Equity
-14.25%
Trailing 12-Months
Asset Growth
-34.22%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong scientific and clinical momentum—multiple programs advancing, encouraging early biomarker and preclinical signals, and disciplined cost reductions—while simultaneously revealing material financial pressure from a steep decline in cash and a large quarter-over-quarter revenue drop. The company maintained guidance for cash runway into 2028 and emphasized partner discussions, but the balance sheet tightening and competitive landscape create meaningful execution and financing risk alongside the positive clinical developments.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$16.45
▲(44.68% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.74% Insiders
19.01% Mutual Funds
23.05% Other Institutional Investors
40.89% Public Companies and
Individual Investors